Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > PASG Passage Bio > Detailed Quotes

PASG Passage Bio

Watchlist
2.380
+0.020+0.85%
Close 07/01 16:00 ET
2.38000.00%
Post Mkt Price 07/01 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.465
Open
2.370
Turnover
529.29K
Low
2.310
Pre Close
2.360
Volume
222.06K
Market Cap
129.25M
P/E(TTM)
Loss
52wk High
15.870
Shares
54.31M
P/E(Static)
Loss
52wk Low
1.570
Float Cap
62.00M
Bid/Ask %
-25.00%
Historical High
38.230
Shs Float
26.05M
Volume Ratio
0.21
Historical Low
1.570
Dividend TTM
--
Div Yield TTM
--
P/B
0.46
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.85%
Amplitude
6.57%
Avg Price
2.383
Lot Size
1
Float Cap
62.00M
Bid/Ask %
-25.00%
Historical High
38.230
Shs Float
26.05M
Volume Ratio
0.21
Historical Low
1.570
Dividend TTM
--
P/B
0.46
Dividend LFY
--
Turnover Ratio
0.85%
Amplitude
6.57%
Avg Price
2.383
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
CEO: Goldsmith M.B.A., Ph.D., Bruce A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top